Skip to main content
. Author manuscript; available in PMC: 2006 May 17.
Published in final edited form as: Br J Dermatol. 2005 Mar;152(3):474–480. doi: 10.1111/J.1365-2133.2005.06217.X

Fig 1.

Fig 1

Corticotropin-releasing hormone receptor type 1 selective agonist (continuous curve, square points) and urocortin I (dotted curve, circle points) attenuate proliferation of HaCaT cells. HaCaT cells were stimulated for 48 h in supplement-free low-calcium EpiLife medium with peptides at graded concentrations. Cell viability was estimated with a MTT test. The results are presented as mean ± SEM (n = 16). Fitting of the dose–response curve was performed with the Prism 4·0 software (GraphPad, San Diego, CA, U.S.A).